Passage Short Term Debt from 2010 to 2025

PASG Stock  USD 0.49  0.01  2.00%   
Passage Bio's Short Term Debt is decreasing over the last several years with slightly volatile swings. Short Term Debt is predicted to flatten to about 3.6 M. During the period from 2010 to 2025 Passage Bio Short Term Debt regressed destribution of quarterly values had coefficient of variationof  20.12 and r-value of (0.67). View All Fundamentals
 
Short Term Debt  
First Reported
2010-12-31
Previous Quarter
3.7 M
Current Value
3.6 M
Quarterly Volatility
1.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.59. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
  
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Latest Passage Bio's Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Passage Bio over the last few years. It is Passage Bio's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Slightly volatile
   Short Term Debt   
       Timeline  

Passage Short Term Debt Regression Statistics

Arithmetic Mean5,990,038
Geometric Mean5,842,688
Coefficient Of Variation20.12
Mean Deviation909,939
Median6,550,000
Standard Deviation1,205,437
Sample Variance1.5T
Range3.2M
R-Value(0.67)
Mean Square Error850.6B
R-Squared0.45
Significance0
Slope(170,528)
Total Sum of Squares21.8T

Passage Short Term Debt History

20253.6 M
20243.7 M
20233.4 M

About Passage Bio Financial Statements

Passage Bio stakeholders use historical fundamental indicators, such as Passage Bio's Short Term Debt, to determine how well the company is positioned to perform in the future. Although Passage Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Passage Bio's assets and liabilities are reflected in the revenues and expenses on Passage Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Passage Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short Term Debt3.7 M3.6 M

Currently Active Assets on Macroaxis

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.07)
Return On Assets
(0.32)
Return On Equity
(0.75)
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.